Phase I study to assess safety, biodistribution and radiation dosimetry for ⁸⁹Zr-girentuximab in patients with renal cell carcinoma.

ABSTRACT:

Purpose

In this phase I study, we evaluated the safety, biodistribution and dosimetry of [⁸⁹Zr]Zr-DFO-girentuximab (⁸⁹Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC).

Methods

Ten eligible patients received an intravenous administration of 37 MBq (± 10%) of ⁸⁹Zr-girentuximab at mass doses of 5 mg or 10 mg. Safety was evaluated according to the NCI CTCAE (version 4.03). Biodistribution and normal organ dosimetry was performed based on PET/CT images acquired at 0.5, 4, 24, 72 and 168 h post-administration. Additionally, tumour dosimetry was performed in patients with confirmed ccRCC and visible tumour uptake on PET/CT imaging.

Results

⁸⁹Zr-girentuximab was administered in te

SUBMITTER: Merkx RIJ 

PROVIDER: S-EPMC8426244 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature